News Perlmutter's Eikon follows the IPO trail Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.
News Remedy Meds buys telehealth rival in $500m marriage Telehealth startup Remedy Meds has expanded its position in the US market at a stroke with a $500m-plus deal to buy Thirty Madison.
News New Trends in Medicine Against Baldness How often have you stared in horror at a comb with a good half of your hair and wished you could stop it falling out at all costs?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.